HCA Healthcare Inc. (NYSE:HCA) on Friday posted upbeat second-quarter earnings.

The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.

HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.

HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

• Barclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.
• Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.
• Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.
• Oppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.
• Truist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.

Considering buying HCA stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.